dacarbazine has been researched along with Endocrine System Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, S; Kiyohara, Y; Namikawa, K; Okuyama, R; Otsuka, Y; Shibagaki, N; Tokudome, T; Tsutsumida, A; Uchi, H; Uhara, H; Yamazaki, N | 1 |
1 trial(s) available for dacarbazine and Endocrine System Diseases
| Article | Year |
|---|---|
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; CTLA-4 Antigen; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; Endocrine System Diseases; Female; Humans; Immunosuppressive Agents; Ipilimumab; Japan; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melanoma; Middle Aged; Neoplasm Proteins; Remission Induction; Treatment Outcome | 2015 |